Document Detail


Factor Xa inhibitors in acute coronary syndromes and venous thromboembolism.
MedLine Citation:
PMID:  19485937     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
As an alternative to the inconvenient and labor intensive traditional anticoagulants, Factor Xa inhibitors may offer new options for the prevention and treatment of acute coronary syndromes (ACS) and venous thromboembolism (VTE). Fondaparinux, an indirect FXa inhibitor, has equivalent efficacy but decreased bleeding risk. It has been recommended by the American College of Cardiology (ACC)/American Heart Association (AHA) as the preferred anticoagulant in ACS patients with higher bleeding risk managed with a noninvasive strategy. Based on the composite results of several clinical trials, fondaparinux is also recommended for VTE prevention in the setting of major orthopedic surgery. Rivaroxaban, a direct FXa inhibitor, appears to have at least equal efficacy and safety to established anticoagulants in the prevention of VTE. With advantages such as oral administration and a wide therapeutic window, it may provide a useful alternative to current anticoagulants. Ongoing studies are exploring its use in treatment of VTE and ACS, as well as prevention of stroke among patients with atrial fibrillation. In this review, we examine the key recent studies on efficacy and safety of FXa inhibitors in ACS and VTE management.
Authors:
Celina M Yong; Andrew J Boyle
Related Documents :
7655497 - Portal hypertension associated with anticardiolipin antibodies in a case of systemic lu...
10603507 - Bleeding complications to long-term oral anticoagulant therapy.
2391307 - Locked in state. a clinicopathological study.
3513727 - Prophylactic anticoagulation following acute myocardial infarction.
2419027 - Differential diagnosis of rhythm disturbances induced by endocardial pacing.
3782637 - Progression of coronary atherosclerotic disease assessed by cinevideodensitometry: rela...
Publication Detail:
Type:  Comparative Study; Journal Article; Review    
Journal Detail:
Title:  Current vascular pharmacology     Volume:  8     ISSN:  1875-6212     ISO Abbreviation:  Curr Vasc Pharmacol     Publication Date:  2010 Jan 
Date Detail:
Created Date:  2010-04-09     Completed Date:  2010-08-02     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101157208     Medline TA:  Curr Vasc Pharmacol     Country:  United Arab Emirates    
Other Details:
Languages:  eng     Pagination:  5-11     Citation Subset:  IM    
Affiliation:
Department of Medicine, Division of Cardiology, University of California San Francisco, San Francisco, CA 94143, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Coronary Syndrome / drug therapy*
Anticoagulants / adverse effects,  pharmacology,  therapeutic use*
Atrial Fibrillation / drug therapy
Factor Xa / antagonists & inhibitors*
Humans
Morpholines / adverse effects,  pharmacology,  therapeutic use
Polysaccharides / adverse effects,  pharmacology,  therapeutic use
Thiophenes / adverse effects,  pharmacology,  therapeutic use
Venous Thromboembolism / drug therapy*,  prevention & control*
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Morpholines; 0/Polysaccharides; 0/Thiophenes; 0/fondaparinux; 0/rivaroxaban; EC 3.4.21.6/Factor Xa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Matrix Metalloproteinases in Vascular Disease - A Potential Therapeutic Target?
Next Document:  Secondary Stroke Prevention with Antithrombotic Drugs.